Trials / Terminated
TerminatedNCT06018506
A Phase I Study of BR108 in Hematological Malignancies
A Phase I ,Single-arm, Open-label Study to Evalute the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Clinical Activity of BR108 Injection in Subjects With Hematological Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- BioRay Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I study of BR108 in hematological malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR108 injection | Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle |
Timeline
- Start date
- 2023-03-18
- Primary completion
- 2024-05-27
- Completion
- 2024-06-21
- First posted
- 2023-08-30
- Last updated
- 2025-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06018506. Inclusion in this directory is not an endorsement.